Navigation Links
Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
Date:6/25/2008

TSX Venture: QPT

EDMONTON, June 25 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT), ("Quest" or the "Company"), today announced interim results from its Phase I/II clinical study designed to investigate appropriate treatment parameters for the potential use of its proprietary compound SL017 for hair removal applications. The interim results represent data from the first 80 patients enrolled in the targeted 100-patient clinical trial.

"The Phase I/II interim results demonstrated that SL017 is safe and well tolerated when used either alone or in combination with photo activation," said Madi Madiyalakan, Chief Executive Officer of Quest. "These results, along with results from the previous clinical trial, support the utility of SL017 for hair removal applications, especially for those who do not benefit from light treatment alone."

To permanently remove unwanted hair, existing laser hair removal techniques require four to eight treatments, and provide only a 75 to 85 percent permanent hair reduction in a limited patient population. The professional laser hair removal market is estimated to be $5 billion worldwide.

Quest is developing SL017 photodynamic therapy (PDT) as a potential hair removal solution that is effective across a broad patient population including those with light colored hair (for example, grey or blonde hair). In a Phase I clinical trial, Quest demonstrated the preferential localization of SL017 in hair follicles, which suggested that cutaneous PDT with SL017 has potential for permanent hair removal applications.

The Phase I/II trial of SL017 was designed to evaluate the effect of skin treatment on follicular uptake of SL017, assess the tolerable light dose on healthy subjects, and subsequently, determine the efficacy of hair removal under optimal treatment conditions. Results from this study will be used to guide the design of future clinical development.

Skin Pret
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...GO, Nov. 5 Imagenetix, I...at William Spencer, President and CEO of Imageneti...nd annual LD MICRO Conference on Thursday, Decembe...ngeles. ,, About LD MICRO ,, LD MICRO is a b...finding undervalued companies in the micro-cap spa...
(Date:11/5/2009)...LE, Calif., Nov. 5 Cephe...tives will be speaking at the following investor c...ia webcast. , , Credit Suisse Heal...ursday, 12 November, 2009 at 10 a.m. Mountain Time...m, London, England, Tuesday, 1 Dec...
(Date:11/5/2009)...MOUTH MEETING, Pa., Nov. 5 /PRNewswire-Asia-FirstC...("BMP Sunstone" or the "Company") today announced,...09 financial results on,Monday, November 9, 2009, ...ll hold a conference call at 5:00 pm ET on Novembe...Listeners may access the call by,dialing 1-888-713...
(Date:11/4/2009)... The Human Anthrax Vaccine Program mus...ted the feature film "A Call to Arms:2009 Edi... "Fatal Immunity: The Human Anthrax Vaccine S...d present danger of top secret government science ... no accountability to its victims. It is availabl...
Breaking Biology Technology:Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Cepheid to Webcast Upcoming Financial Presentations 2BMP Sunstone to Report Third Quarter 2009 Financial Results 2Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 2Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 3Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 4Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 5Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 6Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 7
...zone and Nitrofurantoine belong to the group of ni...tment of gastrointestinal infections in cattle and...enic effect, nitrofuranes (except for furazolidone... (EWG) No. 2901/93). Furazolidone was prohibited i...o. 1441/95). They are mentioned in appendix IV of ...
... of Edman sequence analysis and electrospray tande... structural data of highlyknotted spider toxins ,...structure determination of disulfide bridged pepti...the Procise cLC 492 sequencing system and the QSTA...ctrometer. These two techniques provide complement...
...lt or generally not to analyse by GC/MS, , ...ter simple solvent extraction , and fast ...ched standards. , The drawback of MS/MS m... each target analyte. This effort can signi...ard parameters, which are given in the attached CD...
Other Biology Technology:Detection of nitrofurane metabolites in food with HPLC/MS/MS 2Efficient Primary Structure Elucidation of Disulfide-bridged Peptides 2Efficient Primary Structure Elucidation of Disulfide-bridged Peptides 3Efficient Primary Structure Elucidation of Disulfide-bridged Peptides 4Efficient Primary Structure Elucidation of Disulfide-bridged Peptides 5Simultaneous Determination of Residues of Approximately 100 Pesticides , and Metabolites in Fruit and Vegetables by LC/MS/MS 2Simultaneous Determination of Residues of Approximately 100 Pesticides , and Metabolites in Fruit and Vegetables by LC/MS/MS 3Simultaneous Determination of Residues of Approximately 100 Pesticides , and Metabolites in Fruit and Vegetables by LC/MS/MS 4Simultaneous Determination of Residues of Approximately 100 Pesticides , and Metabolites in Fruit and Vegetables by LC/MS/MS 5Simultaneous Determination of Residues of Approximately 100 Pesticides , and Metabolites in Fruit and Vegetables by LC/MS/MS 6
(Date:11/8/2009)...ON DESIGNED FOR ADULTS WITH INTELLECTUAL DISABILIT...diana University study involving adults with intel...ed their personal health knowledge after taking a ... ID, an internationally accepted term for mental r... physical inactivity and preventable chronic disea...
(Date:11/6/2009)...50th anniversary this month of the publication of ...f Biological Sciences (AIBS) is publishing open ac...in and his historic insights into evolution. , Th...ty of California, Berkeley, and James T. Costa of ...n Myths About Charles Darwin," appeared in the Oct...
(Date:11/6/2009)...6 Auburn Hills, MI-based Law Enfor...talling its locker system and patent-pending Biome...Department of Health and Human Services, National ... The locker system will support the NIH,s entire p... nation,s medical research agency. The project is...
Breaking Biology News(10 mins):Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 2Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 3As Sleep Improves Grades Seem to Go Up 48427 1As Sleep Improves Grades Seem to Go Up 48427 2MDS Nordion Begins to Manufacture Cardiac Imaging Agent 48425 1MDS Nordion Begins to Manufacture Cardiac Imaging Agent 48425 2MDS Nordion Begins to Manufacture Cardiac Imaging Agent 48425 3MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip 48421 1MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip 48421 2MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip 48421 3
...mental threat has been detected in North American ...ities. , Along with scientists from several Canad...ed biological damage caused by declining levels of...alling the phenomenon "aquatic osteoporosis," Quee...he study, notes that calcium is an essential nutri...
...vernment of Cameroon, and other partners have coll...tect the world,s most endangered great ape: the Cr...n important trans-boundary protected area with Nig...estimated 115 gorillasa third of the Cross River g...ans-boundary protected areas allow species to roam...
...ited States has been under assault for decades by ... is not often that one of these aliens faces a cou...eral other institutions, the University of Rhode I... an insect pest that regularly disfigures birch tr...t. And the credit goes to entomologists from URI ...
Other Biology News:Queen's University biologists find new environmental threat in North American lakes 2New national park protects world's rarest gorilla 2New national park protects world's rarest gorilla 3URI researchers help score knockout punch on birch tree pest 2
Mouse Anti-Lamin B Monoclonal Antibody, Unconjugated, Clone X223 from ImmuQuest Ltd.
Mouse Anti-Vesicular Glutamate Transporter 2 (VGLUT2) Antibody, Unconjugated from CHEMICON
QCapture Pro Software from QImaging
Rabbit Anti-VEGF Receptor 2, phospho (Tyr1214) Polyclonal Antibody, Unconjugated from Abcam
Biology Products: